A cross‐sectional study of psoriasis triggers among different ethno‐racial groups
Sign Up to like & getrecommendations! Published in 2017 at "Journal of the American Academy of Dermatology"
DOI: 10.1016/j.jaad.2017.04.1109
Abstract: Dr Bissonnette has received grants and research support, served as a consultant or received honoria from AbbVie, Amgen, Apopharma, Boehringer Ingelheim, Celgene, Dermira, Eli Lilly, Galderma, GSK-Stiefel, Merck, Incyte, Janssen, Kineta, Leo Pharma, Merck, Novartis,… read more here.
Keywords: leo pharma; eli lilly; celgene; merck ... See more keywords
P135 Efficacy and safety of upadacitinib in TNFi inadequate responders with rheumatoid arthritis from three Phase 3 clinical trials
Sign Up to like & getrecommendations! Published in 2023 at "Rheumatology"
DOI: 10.1093/rheumatology/kead104.176
Abstract: For patients with RA who are refractory to biologic disease-modifying antirheumatic drugs (bDMARDs), such as tumor necrosis factor inhibitors (TNFis), optimal disease control is less likely to be achieved with subsequent therapy. In line with… read more here.
Keywords: bristol; amgen; abbvie amgen; janssen ... See more keywords
OP0010 Effect of denosumab compared with risedronate in glucocorticoid-treated individuals: results from the 12-month primary analysis of a randomized, double-blind, active-controlled study
Sign Up to like & getrecommendations! Published in 2017 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2017-eular.3164
Abstract: Background Glucocorticoid (GC)-induced osteoporosis (GIOP) remains the most common secondary cause of osteoporosis. Despite approved therapies, many subjects do not receive GIOP prevention or treatment. There is increased RANKL and decreased osteoprotegerin (OPG) expression in… read more here.
Keywords: research support; treatment; study; grant research ... See more keywords
OP0048 Romosozumab rapidly reduces clinical vertebral fracture incidence: results from the frame study
Sign Up to like & getrecommendations! Published in 2017 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2017-eular.5796
Abstract: Background Romosozumab (ROMO) inhibits sclerostin and has a dual effect on bone, increasing formation while decreasing resorption, resulting in significant increases in bone mineral density (BMD) at 6 months (m), which at 12m reach 13.3%… read more here.
Keywords: research; clin vfx; amgen; romo ... See more keywords
OP0017 The impact of the duration of bisphosphonate drug holidays on hip fracture rates
Sign Up to like & getrecommendations! Published in 2018 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2018-eular.4953
Abstract: Background Given FDA warnings, drug holidays (temporary or permanent discontinuation) of bisphosphonates (BPs) after long-term (3–5 years) continuous therapy is becoming increasingly common in the United States (US). However, the benefits and risks of stopping… read more here.
Keywords: drug holiday; fracture; drug; hip fracture ... See more keywords
AB0522 SAFETY PROFILE OF UPADACITINIB UP TO 3 YEARS IN PATIENTS WITH PSORIATIC ARTHRITIS: AN INTEGRATED ANALYSIS FROM THE PHASE 3 PROGRAM
Sign Up to like & getrecommendations! Published in 2021 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2021-eular.395
Abstract: The efficacy and safety of upadacitinib (UPA), an oral Janus kinase inhibitor, in patients (pts) with active psoriatic arthritis (PsA) were demonstrated through 24 weeks in the phase 3 SELECT-PsA 1 and SELECT-PsA 2 placebo-controlled… read more here.
Keywords: roche; ada; amgen; abbvie ... See more keywords
AB0529 CHARACTERIZATION OF REMISSION IN PATIENTS WITH PSORIATIC ARTHRITIS TREATED WITH UPADACITINIB: POST-HOC ANALYSIS FROM TWO PHASE 3 TRIALS
Sign Up to like & getrecommendations! Published in 2021 at "Annals of the Rheumatic Diseases"
DOI: 10.1136/annrheumdis-2021-eular.574
Abstract: For patients (pts) with PsA, several disease activity measures are available including very low/minimal disease activity (VLDA/MDA), cutoffs based on the Disease Activity in PsA (DAPSA) score, and on the Psoriatic Arthritis Disease Activity Score… read more here.
Keywords: janssen; abbvie amgen; amgen; pfizer ... See more keywords
P05 Cardiac safety of the trastuzumab biosimilar ABP 980 in women with HER2-positive early breast cancer in the LILAC study
Sign Up to like & getrecommendations! Published in 2019 at "International Journal of Gynecological Cancer"
DOI: 10.1136/ijgc-2019-esgo.70
Abstract: Introduction/Background Although well-tolerated, trastuzumab can lead to severe heart failure in 2–4% of patients. In the phase 3 LILAC trial, trastuzumab biosimilar ABP 980 demonstrated similar efficacy, safety, and immunogenicity to trastuzumab reference product (RP)… read more here.
Keywords: cardiac safety; amgen; safety; abp 980 ... See more keywords
Sex Differences in Multiple Myeloma Biology and Clinical Outcomes: Results from 3894 Patients in the Myeloma XI Trial
Sign Up to like & getrecommendations! Published in 2019 at "Blood"
DOI: 10.1182/blood-2019-128041
Abstract: Introduction: Multiple myeloma (MM) is more common in men than women but the mechanism(s) driving this are not understood. In our previous study (Myeloma IX) we found sex disparities in the cytogenetic lesions present in… read more here.
Keywords: consultancy honoraria; celgene; janssen; amgen ... See more keywords
Evaluation of a FLT3 Bite® for Acute Myeloid Leukemia
Sign Up to like & getrecommendations! Published in 2017 at "Blood"
DOI: 10.1182/blood.v130.suppl_1.1354.1354
Abstract: Acute myeloid leukemia (AML) is a disease with high unmet medical need. Standard induction chemotherapy can lead to complete remission in patients with a favorable genetic risk profile; however, about half of patients are ineligible… read more here.
Keywords: amgen inc; research; bite; flt3 ... See more keywords
Superior Efficacy of Carfilzomib and Dexamethasone (Kd56) Vs Bortezomib and Dexamethasone (Vd) in Multiple Myeloma (MM) Patients with Moderate or Serious Renal Failure: A Subgroup Analysis of the Phase 3 Endeavor Study
Sign Up to like & getrecommendations! Published in 2017 at "Blood"
DOI: 10.1182/blood.v130.suppl_1.1845.1845
Abstract: Background: Carfilzomib, a second generation selective proteasome inhibitor, is approved in the United States and other countries for the treatment of relapsed or refractory multiple myeloma (RRMM). In the randomized, phase 3 study ENDEAVOR, Kd56… read more here.
Keywords: kd56; speakers bureau; dexamethasone; oncology ... See more keywords